Cantor Fitzgerald initiated coverage on Affimed Therapeutics with a new price target

2/23/22 7:41:02 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Cantor Fitzgerald initiated coverage of Affimed Therapeutics with a rating of Overweight and set a new price target of $12.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AFMD

Date	Price Target	Rating	Analyst
5/14/2025		Buy → Neutral	H.C. Wainwright
5/13/2025		Outperform → Market Perform	Leerink Partners
12/12/2022	$6.00	Buy	H.C. Wainwright
10/10/2022	$9.00 → $2.00	Buy → Hold	Stifel
8/18/2022		Overweight	Wells Fargo
3/31/2022	$7.00	Overweight	Piper Sandler
2/23/2022	$12.00	Overweight	Cantor Fitzgerald
10/21/2021	$10.00	Buy	Truist